- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Ribosilide is a CDK4/6 inhibitor for advanced or metastatic breast cancer with HR positive and HER2 negative. Standardized medication is the fo...
Close attention should be paid to the safety of the heart, liver, and blood system during the treatment of Rabosinib. QT interval prolongation,...
Ribociclib plays an important role in various cancer treatments, but not all patients are suitable. There are significant risks associated with...
Ribosilide is a CDK4/6 inhibitor, which has definite efficacy in the treatment of breast cancer, but neutropenia, nausea and fatigue are the mo...
Ritlecitinib is a daily oral JAK inhibitor, and its standardized use requires close attention to three major aspects: standard dosage, efficacy...
Before using Ritlecitinib, clearly defining contraindications is the first line of defense against serious adverse events. The following two co...
Proactively managing key risks such as infection, liver injury, and vaccine administration during the use of rituximab is a core aspect of ensu...
Litaxitinib regulates abnormal activity of the immune system by intervening in specific signaling pathways, thereby helping to restore hair gro...
The indications for Voranigo are clear, mainly targeting patients with grade 2 astrocytomas or oligodendrogliomas who have undergone surgery, i...
The indications for Voranigo are clear, mainly targeting patients with grade 2 astrocytomas or oligodendrogliomas who have undergone surgery, i...
